DTAT for Pharma Investors


April 17, 2019

Pharma investors’ tolerance for 1-size-fits-all dose finding continues to astonish me. In this short video, I put the case for making early-phase trial methodology an issue in the boardroom.

The video features this R Shiny app. Details of the pharmacoeconomic argument made here may be found in my bioRxiv preprint,  Costing ‘the’ MTD.